awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q35088670-9F6641CF-E0D9-4EDD-8F65-A9C4C10D496A
Q35088670-9F6641CF-E0D9-4EDD-8F65-A9C4C10D496A
BestRank
Statement
http://www.wikidata.org/entity/statement/Q35088670-9F6641CF-E0D9-4EDD-8F65-A9C4C10D496A
Classification of non-small cell lung cancer based on copy number alterations
P2860
Q35088670-9F6641CF-E0D9-4EDD-8F65-A9C4C10D496A
BestRank
Statement
http://www.wikidata.org/entity/statement/Q35088670-9F6641CF-E0D9-4EDD-8F65-A9C4C10D496A
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
6722f5e8cf4e7e9d5415e09f6b438ed6c2ecc887
P2860
FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer.